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S U M M A R Y
Objectives: Ferric siderophore complexes are produced by most bacteria to acquire iron, a vital element.
These complexes are transported across the outer membrane by receptor proteins commonly known as
FepA (ferric enterobactin protein). In this study we attempted to evaluate the immunogenicity of the
membrane protein FepA, aiming at inhibition of iron uptake to protect invasion of the host by the
bacterium.
Methods: The genomic fepA gene was ampliﬁed from Escherichia coli O157:H7. The PCR product was
ligated into pET28a and was then expressed in E. coli BL21(DE3). The recombinant protein puriﬁed by
nickel–nitrilotriacetic acid (Ni–NTA) afﬁnity chromatography was injected into BALB/C mice to induce
immunity. Antibody titer was determined by ELISA.Mouse groupswere challengedwith various doses of
E. coli O157:H7, Shigella ﬂexneri, Klebsiella pneumoniae, and Salmonella typhi to study immune response.
Results: An 85-kDa recombinant protein was expressed and puriﬁed. Immunogenicity of the
recombinant protein was determined by injecting BALB/C mice. The antibody produced therein could
efﬁciently recognize and bind ferric enterobactin binding protein. Immunized mice challenged with
higher doses of selected bacteria survived.
Conclusions: Signiﬁcant recognition by the antibody of ferric enterobactin binding proteinmay lead to its
application in the restriction of Enterobacteriaceae propagation.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
International Journal of Infectious Diseases
journa l homepage: www.e lsev ier .com/ locate / i j id1. Introduction
Iron is an important micronutrient for virtually all living
organisms, except lactic acid bacteriawheremanganese and cobalt
are used in place of iron. Under aerobic conditions, free iron
abundance is limited by the very low solubility of ferric
hydroxide.1 It acts as a cofactor for the redox-dependent enzymes
involved in most cellular processes, including electron transfer,
RNA synthesis, and resistance to reactive oxygen intermediates.2
Under physiological conditions, iron can exist in either the reduced
ferrous form (Fe2+) or the oxidized ferric form (Fe3+). The redox
potential of Fe2+/Fe3+ makes iron extremely versatile when it is
incorporated into proteins as a catalytic center or as an electron
carrier.3
Bacteria have developed various ways to circumvent an iron
shortage,4,5 and these generally rely on receptor proteins at the
bacterial surface that bind speciﬁcally to a wide range of iron-
containing molecules. For many pathogens, these ligands can be
the iron-binding proteins that the host itself uses to keep Fe3+ in
solution (e.g., transferrin), whereas others produce hemophores.* Corresponding author. Tel.: +98 21 51212600; fax: +98 21 51212601.
E-mail address: rasooli@shahed.ac.ir (I. Rasooli).
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doi:10.1016/j.ijid.2009.12.009To overcome the iron-restricted condition in their mammalian
hosts, coliform bacteria may utilize one or more iron assimilation
systems to take up iron within a particular environmental niche in
the host.4 Possession of iron uptake systems is known to be
important in bacterial pathogenesis.
High-afﬁnity iron uptake systems are widely utilized by
coliform bacteria to take up iron in the host milieu. These involve
the synthesis of a low molecular mass siderophore, the expression
of iron-regulated outermembrane proteins (IROMPs) and enzymes
to utilize the chelated iron.4 Gram-negative bacteria take up ferric-
siderophore complexes via speciﬁc outer membrane (OM)
receptors in a process that is driven by the cytosolic membrane
(CM) potential and mediated by the energy-transducing TonB–
ExbB–ExbD system. Periplasmic binding proteins shuttle ferric-
siderophores from the OM receptors to CM ATP-binding cassette
(ABC) transporters, which in turn deliver the ferric-siderophores to
the cytosol where the complexes are probably dissociated by
reduction.6
Escherichia coli excrete the catecholate siderophore enterobac-
tin in response to iron deprivation, to solubilize iron prior to
transport. Ferric enterobactin protein (FepA) is a Gram-negative
bacterial OMprotein that transports ferric enterobactin. FepA from
E. coli is a 724-residue integral OM protein that transports ferric
enterobactin into the periplasm. FepA is composed of twoses. Published by Elsevier Ltd. All rights reserved.
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with connecting loops (residues 154–724); and (2) an N-terminal
globular domain consisting of two long loops, several short b-
strands and single-turn helices (residues 1–153) that fold into the
barrel, plugging the barrel pore. The b-barrel domain has the
following three main features: 10 short periplasmic loops that
range in length from 2 to 10 residues, the 22-strand b-barrel, and
11 extracellular loops. The lengths of these extracellular loops can
range from 2 to 37 residues, consequently comprising roughly 40–
50% of the total b-barrel. The extracellular loops can extend 30–
40 A˚ above the OM. Their presumed role is to initially interact with
the ferric-siderophore as well as occlude the opening of the b-
barrel to prevent the access of unwanted solutes.7 These data
support the idea that the production of antibody against FepAmay
contribute to protection against Gram-negative bacteria8 with
higher fepA gene homologies. On the basis of the above criteria the
present work was designed focusing on the cloning and expression
of the fepA gene and studying the immunoactivity of its
recombinant protein.
2. Materials and methods
2.1. Chemicals and enzymes
T4 DNA ligase was purchased from Fermentas (Vilnius,
Lithuania). Restriction endonucleaseswere obtained fromCinnagen
(Tehran, Iran). All other chemical reagents were from Sigma
(Munich, Germany) or Merck (Darmstadt, Germany). The gel
puriﬁcation kit and plasmid extraction kit were from Bioneer
(Daejeon, Korea). Nickel–nitrilotriacetic acid (Ni–NTA) agarose was
fromQiagen (Valencia, USA). Primers were synthesized by Bioneer .
2.2. Bacterial strains, plasmids, and culture media
E. coli Ol57:H7 (ATCC 43889), Shigella ﬂexneri (NTCC 12678),
Klebsiella pneumoniae (ATCC 13883), and Salmonella typhi (PTCC
1609) were used. The plasmid pET28a(+) was a Novagen product
(USA). E. coli BL21(DE3) was purchased from Cinagen (Iran). E. coli
strains were cultivated in Luria–Bertani (LB) broth or LB agar at
37 8C. E. coli transformants were grown on LB medium containing
50 mg/ml ampicillin.
2.3. Construction of plasmid
The gene coding for ferric enterobactin binding protein (fepA)
from E. coli Ol57:H7 was ampliﬁed from its genomic DNA via PCR.
The forward (50-TAAAGGATCCATGAACAAGAAGATTC-30) and re-
verse (50-AGCAGTCGACGAAGTGAGTGTTTAC-30) primers were
used to amplify the fepA gene with the stop codon truncated in
order to be fused with a downstream His-tag sequence on the
vector (BamH1and SalI restriction enzyme sites underlined). PCR
conditions consisted of 5ml (50 ng/ml) DNA, 1 ml of each primer
(20 pM), 250mM each dNTP, 40 mM KCl, 40 mMMgCl, and 1ml of
2.5 U Taq DNA polymerase in a ﬁnal volume of 50 ml on a thermal
cycler (Techne Gradient, Staffordshire, UK). The PCR procedurewas
as follows: initial denaturation at 948 C for 5 min and 35 cycles of
1 min at 94 8C, 1 min at 55 8C, 3 min at 72 8C, followed by an
additional 5 min at 72 8C. The ampliﬁed DNA products were
electrophoresed in a 0.8% (w/v) agarose gel. The PCR products
(2241 bp for fepA) were puriﬁed using a PCR puriﬁcation kit as per
the manufacturer’s instructions. The PCR product was digested
with BamH1 and SalI and cloned into pET28a(+) vector digested
with the same endonucleases. The new construct was named
pET28a–FepA. The recombinant DNA was transformed into E. coli
strain BL21(DE3) as an expression host. The transformants were
selected on LB agar containing 50 ng/ml ampicillin. Aftermini-scaleisolation of the plasmid DNA using the plasmid extraction kit, the
presence of the open reading frame (ORF) was conﬁrmed by
restriction analysis and by sequencing.
2.4. Expression and puriﬁcation of FepA protein
A single bacterial colony was used to inoculate 5 ml of LB broth
containing 50mg/ml ampicillin. The culture was shaken at 200 rpm
at 37 8C overnight andwas thenused to inoculate 100 ml of LB broth
with 50mg/ml ampicillin in a 500 ml ﬂask. At the optical density of
0.6 at 600 nm, 1 mM isopropylb-D-thiogalactoside (IPTG) was used
for induction . The culture was further shaken at 37 8C for 4 h and
was thenharvestedby centrifugation at 5000 rpmat4 8C for10 min.
The pellets were suspended in phosphate-buffered saline (PBS, pH
7.4) and boiled at 100 8C for 5 min with the sample buffer solution.
The recombinant FepA was puriﬁed by Ni–NTA afﬁnity chromatog-
raphy. The cell pellet was thawed at 4 8C and resuspended in lysis
buffer, followed by the addition of lysozyme at 1 mg/ml; it was then
incubated on ice for 30 min. The lysatewas then sonicated (6 times,
10 s at 200Wwith a 10 s cooling period between eachburst) using a
sonicator equippedwith amicrotip. The lysatewas then centrifuged
at 8500 rpm for 25min at 4 8C to pellet the cellular debris. The
supernatant was loaded onto an Ni–NTA agarose column, pre-
equilibratedwith5 ml lysis buffer containing 10 mMimidazole. The
FepA protein was eluted by a stepwise procedure, using buffers
containing 20, 40, 90 and 150 mM imidazole. The fractions were
collected and analyzed by sodium dodecyl sulfate polyacrylamide
gel electrophoresis (SDS-PAGE). The protein fractions pool was
concentrated by freeze-drying. Protein concentration was deter-
mined by the method of Lowry et al.9 using bovine serum albumin
(BSA) as a standard.
2.5. Western blot analysis
Protein samples were electrophoresed on a 9% SDS-PAGE gel
and then electroblotted onto a nitrocellulose membrane at a
constant current of 300 mA at 4 8C for 1.5 h. The membrane was
incubated in the blocking buffer of 3% BSA, with gentle shaking for
1 h at room temperature. The membrane was then washed 3 times
with PBS-T (PBS + 0.05% Tween-20, pH 7.4) before incubation with
the diluted mouse anti-FepA (1:100) serum for 1 h. After the PBS-T
wash, the membrane was incubated with mouse IgG conjugated
with horseradish peroxidase (HRP) for 1 h at room temperature.
The membrane was then washed three times in PBS-T. The
membrane was visualized with diaminobenzidine (DAB) substrate
until brownish bands were observed. Color development was then
terminated by washing in PBS.
2.6. Immunization of mice
Male inbred BALB/c mice, 4–6 weeks old (16–22 g), were
procured from the Pasteur Institute, Tehran, Iran. Animals were
kept inwell aeratedroomsandwere fedona standardpellet diet and
water. Mice were acclimatized to the laboratory conditions for 1
week before use in the experiments. The recombinant protein was
emulsiﬁed with complete Freund’s adjuvant. A total of 40 BALB/c
mice were immunized with 10mg of recombinant protein per
mouse ondays 0, 15, 30 and45, intraperitoneally by injecting 0.2 ml
of antigen/adjuvant mixture under mild analgesia. Blood samples
were collected10dayspost-injection through infra-orbital route.An
additional 10 BALB/c mice served as a control group.
2.7. Analysis of antibody response
Sera were assayed for an antibody response against the
recombinant protein by ELISA. Brieﬂy, 96-well microtiter plates
Figure 1. PCR ampliﬁcation of FepA gene from E coli 0157 H7. PCR product was
visualized on 1% agarose Lane 1: molecular matker; Lane 2, FepA gene (2241 bp);
Lane 3, FepA gene digested by restriction enzymes.
Figure 2. SDS-PAGE analysis of periplasmic extract showing a single band of FepA.
Lane 1, Molecular marker; Lanes F1, F2, ﬁrst unbound protein ﬂow; Lanes W1–W3,
column washed with buffer; Lanes E1, E2, column washed with elution buffer.
Figure 3.Mean antibody titres achieved at increasing times following immunization.
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dilutions of each serum ranging from 1:400 to 1:51 200 were
added to the wells in triplicate. Antibodies binding to the antigen
were detected using anti-mouse IgG conjugated with HRP at
1:2000 dilution. The color was developed with orthophenylene-
diamine (OPD) for 30 min and the reaction was stopped with 2 M
H2SO4. The plates were then read with a microplate reader at
492 nm. Results were considered positive if the absorbance was at
least double that of the control sera and the antibody titers were
scored as the highest positive dilution.10
2.8. Determination of bacterial lethal dose (LD50)
E. coli O157:H7, S. ﬂexneri, K. pneumoniae, and S. typhi at doses
ranging from 2  l04 to 2  l09 CFU/ml were administered
intraperitoneally to four groups of BALB/c mice with 10 animals
per group. Mortality in the mice was recorded for two consecutive
post-challenge days.
2.9. Mouse challenge experiment
The immunized and control groups were challenged by
intraperitoneal injection with 1 ml of live microbial suspensions
at microbial log phase.
2.10. Bactericidal assay of anti-FepA antibody
The bactericidal activity of anti-FepA serum raised inmicewas
assayed by the method given by Chen et al.11 The complement
source for the experiment was fresh human serum from healthy
individuals. Serial dilutions of the heat-inactivated anti-FepA
serum were prepared. The bactericidal assay was performed by
mixing 100 ml of bacterial suspension (approximately 2  106
organisms) in PBS (containing 1 mM CaCl2 and 0.2 mM MgCl2)
with 50 ml of heat-inactivated serum and incubating for 30 min at
4 8C. About 30 ml of the complement containing serum was then
added (1:10 diluted) to give a ﬁnal concentration of 20% and the
mixture was incubated overnight at 37 8C in 96-well plates. The
following morning, the samples from wells were plated on
nutrient agar plates and allowed to incubate overnight at 37 8C.
The controls for this assay consisted of: (1) bacterial suspensio-
n + immune serum + heat-inactivated complement; (2) bacterial
suspension + pre-immune serum + fresh complement; (3) bacte-
rial suspension + pre-immune serum + heat-inactivated comple-
ment. Colony forming units (CFU) were calculated after
incubation of nutrient agar plates and % killing was calculated
as follows: ((CFU from control  CFU from sample)/CFU from
control)  100.
3. Results
3.1. PCR ampliﬁcation of the fepA gene
The fepA gene of E. coli Ol57:H7 was successfully ampliﬁed by
PCR and cloned into pET28a(+) vector. This construct was
conﬁrmed by restriction enzyme analysis (Figure 1) and by DNA
sequencing. The pET28a(+)–FepA was transformed into BL21(DE3)
E. coli cells for overexpression of the recombinant FepA with a C-
terminal His-tag.
3.2. Expression and puriﬁcation
The recombinant FepA protein was over-produced after IPTG
induction. Following His-tagged afﬁnity chromatography, the
puriﬁed recombinant protein analysis with SDS-PAGE revealed a
single band of approximately 85 kDa (Figure 2).3.3. Antibody response
Signiﬁcantly high antibody was detected in the test group by
ELISA compared with the control group injected with PBS
(Figure 3).
3.4. Western blot analysis
The speciﬁcity of the recombinant protein was determined by
Western blot analysis using FepA protein with antiserum.
Production of recombinant FepA protein was reconﬁrmed in
iron-restricted medium. The antibody was speciﬁcally reacted
with the recombinant protein (Figure 4).
Figure 4. Western blot analysis of bacterial FepA protein with antiserum. Lane 1,
Molecular weight marker; Lane 2, cleared cell lysate; Lane 3, the puriﬁed
recombinant FepA; Lane 4, periplasmic extraction of bacterial cells grown in iron
restricted medium; Lane 5, periplasmic extraction of bacterial cells grown in iron
rich medium.
Table 1
Response of immunized mice to bacterial challenge
LD50 Challenge dose Challenge dose LD50 % Survival % Homology with E. coli fepA gene
Escherichia coli O157:H7 7108 1.51014 2.14106 90 100
Shigella ﬂexneri 4104 81013 2109 100 98
Klebsiella pneumoniae 4104 51013 1.25109 83.33 79
Salmonella typhi 2104 11010 5105 75 52
LD, lethal dose.
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The LD50 of E. coli O157:H7, S. ﬂexneri, K. pneumoniae, and S.
typhi for BALB/cmicewere determined as 7  108, 4  104, 4  104,
and 2  104 CFU, respectively. All the mice but the immune ones
died within 24–72 h. Postmortem examinations were performed
on the dead animals and bacteria were isolated from liver and
spleen. The serum of immunized mice was capable of protecting
mice from live bacterial challenge (Table 1).
3.6. Bactericidal assay of anti-FepA antibody
Sera at 1:10 and 1:20 dilutions showed an average of 81.51%
and 73.14% bactericidal properties, respectively.
4. Discussion
It is well established that iron-regulated OM proteins are
expressed under iron-deﬁcient growth conditions. In the present
study, FepA from E. coli O157:H7 was cloned and puriﬁed in order
to evaluate its protective potential in the animal model via
intraperitoneal route of administration. Vaccination with recom-
binant FepA derived from the corresponding genes of E. coli
O157:H7 strain protected against infection by E. coli and other
bacterial strains (Table 1). A comparative analysis of the lethal dose
of E. coli O157:H7 when injected into control and immune mice
showed non-lethal in immunized mice. In this study, the serum of
immunizedmicewas capable of protectingmice from live bacterial
challenge. The antibody produced by FepA from one bacterial
strain could protect the mice against the other three bacteria used
in this study. It may be deduced that anti-FepA antibodies haveinterfered with the iron uptake ability, thereby inhibiting bacterial
growth. This is in agreement with Meyer et al.12 and Pintor
et al.13,14 who showed the speciﬁc block of iron uptake via
siderophore and transferrin using polyclonal and monoclonal
antibodies against IROMPs of Pseudomonas sp and Neisseria sp,
respectively. FepA is conserved between all the strains investigat-
ed, with 52–100% identity in the nucleotide and amino acid
sequence (data not shown). Hence, FepA, as expected, potentially
induced protection against the bacterial strains under study. These
results indicate that FepA is likely to induce protection against
most Enterobacteriaceae and could be an attractive vaccine
candidate.
The bacterial iron limitation inducible OM proteins hold a
promise for vaccine development, since they expose a substrate-
binding domain at the cell surface, which must be conserved for
function.15 If the immune system could be directed against this
domain, an effective, broadly cross-reactive vaccine could possibly
be developed. In order to practically arrive at such a conclusion,
further study of cross-immunity using recombinant FepA derived
from each of the pathogens is suggested.
The quantitative bacterial counts determined in the bactericidal
assay showed an average four-fold decrease in the bacterial counts
compared with controls. The 73.14–81.51% bactericidal property
obtained emphasizes the role of humoral immunity against E. coli
infection. Therefore growth inhibition of the bacterium was
accomplished as a result of blocking the uptake of iron. This is
in agreement with earlier observations where anti-IROMP anti-
bodies signiﬁcantly reduced E. coli septicemia and severity of gross
lesions in turkeys.16
The periplasmic extraction of bacterial cells grown in iron-
restrictedmedium showed FepA production, while the cells grown
in iron-rich medium did not produce FepA (Figure 4). These
ﬁndings further support the idea that the mechanism of iron
uptake may constitute an important virulence factor, which can
help in establishing infection in the host.17 The study of this
virulence system may lead to a better understanding of bacterial
pathogenesis, especially in pathogens like E. coli. Additional
investigations are required to assess the effects of different mouse
strains, routes of immunization, and mucosal adjuvants on the
types of immune response induced by vaccination with FepA. It
will be interesting to further explore the mechanism of FepA
protection. In future studies, different immunization procedures,
adjuvants, cross-immunity studies using recombinant FepA
derived from each of the pathogens, delivery vectors and animal
models should be considered to make it applicable in both the
human and large animals.
5. Conclusions
Immunization with FepA protein from E. coli O157:H7 can
protect against infection with E. coli O157:H7, S. ﬂexneri, K.
pneumoniae, and S. typhi further supporting the use of this antigen
as a potential vaccine candidate. Future research will investigate
the most effective vaccination schedule for preventing E. coli
infections and whether this antigen is more effective in combina-
tion with other novel E. coli vaccine candidates.
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